COLORADO SPRINGS, Colo., Nov. 9, 2012 /PRNewswire/ -- Cannabis Science Inc., (OTC: CBIS) is pleased to announce an opportunity to directly respond to our investors regarding our corporate developments and preclinical initiatives via a 1st Q of 2013 webinar investor call. As we continue to build our team of world-renowned experts to bring CS-S/BCC-1 and CS-TATI-1 through our preclinical investigation and into subsequent human clinical studies to satisfy the FDA regulatory process for market approval both domestically and internationally.
Dr. Robert Melamede, President and CEO, states, "Over the past 3 quarters the company has successfully initiated a strong biomedical research program for the scientific investigation of our lead compound to demonstrate the anti-viral and anti-oncogenic properties based on multiple signaling pathways of cannabinoid therapeutics. In doing so we have initiated the preclinical development and initial product management of CS-TATI-1 and CS-BCC/SC-1 by appointing, Christopher Meenan MS, MBA as Executive VP of Product Research and Development, Ron Sekura PhD as Executive VP of Regulatory Affairs, Roscoe Moore DVM, MPH, PhD, Mariel Selbovitz MPH, Thomas August MD, and Dorothy Bray PhD, to the CBIS SAB team."
Cannabis Science is appointing a Chief Medical Officer and a Chief Scientific Officer to satisfy the regulatory requirements to enter into human clinical studies of CS-TATI-1 and CS-BCC/SC-1 in 2013. The Company expects to also begin initial regulatory review for consideration by federally sponsored clinical research networks in parallel to the Companies own investigations. These appointments will provide the Company with invaluable guidance as it undertakes unprecedented studies towards the commercialization of medicinal cannabinoids.
Cannabis Science's research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1's, PO1's and SBIRS which exist to support preclinical development of target validation and proof of concept studies. These studies will be implemented through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).
Cannabis Science is currently working to develop preclinical investigations of CS-S/BCC-1 treatment of basal and squamous cell carcinomas. The Company has begun preclinical investigations, which are being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi's sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.
About Cannabis Science, Inc.
Cannabis Science, Inc. is conducting cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products. Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
President and CEO
Dr. Robert J. Melamede, 888-889-0888
VP of Investor Relations
Robert Kane, 561-234-6929
SOURCE Cannabis Science, Inc.